Medication info
DiZantin Tablet (Valsartan)

DiZantin Tablet (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Korea United Pharm, Co., Ltd.
Appearance
Pale red round film-coated tablet
Packaging
For domestic use: 30 tablets/bottle For export: 98 tablets (14 tablets/PTP x 7), 30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 200806017 · Notified 2008.05.29 · Insurance code 644306210

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
* 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more once daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Essential hypertension — Children and adolescents under 18 years: Safety and efficacy have not been established. Pediatric population — Children and adolescents under 18 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Korea United Pharm, Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used for the treatment of essential hypertension. It is also helpful for patients with heart failure who are intolerant to ACE inhibitors, especially those classified as NYHA Class II to IV. Furthermore, it is effective in reducing the risk of mortality after myocardial infarction in stable patients with left ventricular dysfunction or left ventricular systolic dysfunction. Thus, this drug helps in blood pressure control, improvement of heart function, and better prognosis after myocardial infarction.

How to take

Adult dose

* 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more once daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Essential hypertension — Children and adolescents under 18 years: Safety and efficacy have not been established. Pediatric population — Children and adolescents under 18 years: Safety and efficacy have not been established.

Precautions

This drug can cause serious harm to the fetus if taken during pregnancy, especially after the second trimester, so usage must be stopped immediately upon confirmation of pregnancy. Patients with allergies to this drug or its ingredients, patients who are pregnant, patients with severe liver disease or very poor kidney function, and patients with a history of certain vascular edema should not take this drug. Elderly patients, patients with hyperkalemia, patients with mild to moderate liver impairment, patients with heart valve disease, and patients after heart failure or myocardial infarction should use this drug with caution, and it is important to periodically check blood pressure and kidney function. During the use of this drug, side effects such as dizziness, headache, fatigue, cough, diarrhea, and nausea may occur, and rarely serious adverse reactions such as angioedema, kidney failure, hepatitis, hypoglycemia, and rhabdomyolysis may appear, requiring immediate consultation with medical personnel if symptoms arise. This drug can cause a rapid drop in blood pressure, so patients undergoing dialysis, those taking diuretics, and those on strict salt restrictions should monitor for symptoms of hypotension closely. Interactions may occur if taken with other antihypertensives, potassium-sparing diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), lithium preparations, etc., so it is essential to inform medical personnel. The use of this drug in nursing women is not recommended, and nursing should be suspended if unavoidable. Safety and efficacy have not been established in children or adolescents under 18, so its use is not recommended. In case of overdose, severe hypotension or decreased consciousness may occur, requiring immediate emergency measures as dialysis is ineffective. This drug should be stored out of reach of children and should not be transferred to other containers for safety.

Side effects

  • headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 38 more
  • stomachache
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • kidney dysfunction
  • hyperkalemia
  • angioedema
  • heart failure
  • arrhythmia
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite
  • malaise
  • vascular edema
  • erythema
  • itching
  • serum sickness
  • vasculitis
  • hepatitis
  • syncope
  • epistaxis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • decreased erythrocyte volume
  • decreased hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain effectiveness.

Appearance and packaging

Appearance

Pale red round film-coated tablet

Package unit

For domestic use: 30 tablets/bottle For export: 98 tablets (14 tablets/PTP x 7), 30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.